Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Harvard Business School
Mallinckrodt
Colorcon

Last Updated: January 27, 2023

Onabotulinumtoxina - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Recent Clinical Trials for onabotulinumtoxina

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AbbViePhase 2
Naval Medical Center Camp LejeunePhase 3
University of Alabama at BirminghamPhase 1/Phase 2

See all onabotulinumtoxina clinical trials

Recent Litigation for onabotulinumtoxina

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company2021-06-07
In re: Aoki2013-07-30

See all onabotulinumtoxina litigation

PTAB Litigation
PetitionerDate
Eli Lilly and Company2022-04-11
2017-02-21

See all onabotulinumtoxina litigation

Pharmacology for onabotulinumtoxina
Mechanism of ActionAcetylcholine Release Inhibitors
Physiological EffectNeuromuscular Blockade
Established Pharmacologic ClassAcetylcholine Release Inhibitor
Neuromuscular Blocker
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for onabotulinumtoxina Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for onabotulinumtoxina Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Allergan, Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 See Plans and Pricing 2017-07-15 Company disclosures
Allergan, Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 See Plans and Pricing 2013-12-28 Company disclosures
Allergan, Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 See Plans and Pricing 2013-12-28 Company disclosures
Allergan, Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 See Plans and Pricing 2013-12-28 Company disclosures
Allergan, Inc. BOTOX COSMETIC onabotulinumtoxina For Injection 103000 See Plans and Pricing 2017-07-15 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for onabotulinumtoxina Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for onabotulinumtoxina

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SPC/GB13/078 United Kingdom See Plans and Pricing PRODUCT NAME: BOTULINUM TOXIN TYPE A; REGISTERED: FI 263103-5/2012 20130116; UK PL 00426/0118 - 0061 20130904; UK PL 00426/0074 - 0139 20130904; UK PL 00426/0119 - 0047 20130904
132013902177250 Italy See Plans and Pricing PRODUCT NAME: TOSSINA BOTULINICA DI TIPO A(BOTOX); AUTHORISATION NUMBER(S) AND DATE(S): NL25449, 20110826;034883013/M, 20130123
C02145629/01 Switzerland See Plans and Pricing FORMER OWNER: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, US
C300564 Netherlands See Plans and Pricing PRODUCT NAME: BOTULINUM TOXINE; NAT. REGISTRATION NO/DATE: RVG 32957RVG 17379RVG 32958 2012270627; FIRST REGISTRATION: NL 25449 20110822
122008000043 Germany See Plans and Pricing PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
McKinsey
Colorcon
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.